Tempest Therapeutics (NASDAQ:TPST) Stock Rating Upgraded by Wall Street Zen

Tempest Therapeutics (NASDAQ:TPST) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tempest Therapeutics in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $30.00.

Tempest Therapeutics Stock Performance

Tempest Therapeutics stock opened at $10.27 on Friday. The company has a 50 day moving average price of $9.78 and a 200 day moving average price of $8.06. Tempest Therapeutics has a 52 week low of $5.33 and a 52 week high of $20.67. The firm has a market capitalization of $45.60 million, a price-to-earnings ratio of -0.70 and a beta of -2.08.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings data on Monday, August 11th. The company reported ($2.07) EPS for the quarter, topping analysts’ consensus estimates of ($3.23) by $1.16. Equities analysts forecast that Tempest Therapeutics will post -1.39 earnings per share for the current fiscal year.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.